Call for papers - Reproduction, Technology and Society, a new section in Reproductive BioMedicine Online
Page URL: https://www.bionews.org.uk/page_150441

Polycystic ovary syndrome may have more than two different subtypes

29 June 2020
Appeared in BioNews 1053

There may be at least two different biologically relevant subtypes of polycystic ovary syndrome (PCOS).

By comparing the genomes of 893 women of European ancestry diagnosed with PCOS, researchers found that these women could be grouped into at least two distinct subsets, which are associated with novel gene regions and which have different biological responses.

'We're starting to make headway on what causes PCOS. It's very frustrating for patients because it's poorly understood and patients often see several physicians before PCOS is diagnosed,' said senior author Dr Andrea Dunaif. 'Through genetics, we're beginning to understand the condition and may have specific targeted therapies in the not-too-distant future.'

PCOS is an infertility disorder that affects at least 15 percent of women of reproductive age. The cause of PCOS is unknown, but it does appear to run in families, suggesting a genetic basis to the disorder. PCOS is currently diagnosed based upon physical features and symptoms, including irregular or missing periods, raised levels of male sex hormones, hirsutism and small cysts on the surface of the ovaries.

There is a variation of symptoms among PCOS patients and this study, conducted by scientists at the Mount Sinai Health System in New York, aimed to discover whether there were any genetic, clinical or biochemical differences that could explain this.

Dr Dunaif and her team identified PCOS subtypes by classifying cases into relative groups called clusters from the results of their previously published PCOS genome-wide association study (GWAS). The clusters were then repeated in an independent group of 263 PCOS cases and the researchers identified two distinct PCOS subtypes: a 'reproductive' group and a 'metabolic' group.

Women in the 'reproductive' group (approximately 23 percent of cases) had raised levels of luteinising hormone (LH), which triggers ovulation, and higher sex hormone-binding globulin (SHBG) levels, a protein that regulates the ability of testosterone to enter its target tissues. In addition, this group had lower insulin levels and a lower body mass index (BMI).

Women in the 'metabolic' group (approximately 37 percent of cases) had raised levels of glucose and insulin and a higher BMI. They also had lower LH and SHBG levels.

The remaining women (approximately 40 percent of cases) had no distinguishable characteristics, with traits of both the metabolic and reproductive subgroups.

The researchers discovered that the subtypes tended to cluster in families and that carriers of rare genetic variants in DENND1A, a gene involved in male hormone production, were more likely to have the reproductive subtype of PCOS.

Rather than a catch-all approach for PCOS patients, the researchers suggest that these distinct forms may benefit from different treatment approaches, as they are underpinned by different biological mechanisms, and this could improve long-term outcomes for patients.

'In contrast to classifying disorders based on expert opinion, this is a very powerful objective approach to categorising syndromes like PCOS into distinct subtypes with different causes, treatment and clinical outcomes, said Dr Dunaif.

This study was published in PLOS Medicine.

RELATED ARTICLES FROM THE BIONEWS ARCHIVE
30 June 2003 - by BioNews 
BioNews reporting from ESHRE conference, Madrid:New research from the UK has shown that polycystic ovarian syndrome (PCOS) is more common in lesbian women presenting for infertility treatment than it is in heterosexual women. PCOS is a common medical condition caused by an imbalance in sex hormones and is associated...
15 November 1999 - by BioNews 
Researchers from University College Hospital and the Middlesex Hospital have successfully treated teenage girls suffering from polycystic ovary syndrome using a drug normally used in diabetes treatment. Affecting one in five women, the condition can lead to weight gain, irregular periods, facial hair and sometimes infertility. The disorder, caused by...
3 May 1999 - by BioNews 
A study has found that an experimental drug which normalises insulin use in the body could be the basis of a treatment for polycystic ovary syndrome, a common cause of infertility. Affecting between 5 and 10 percent of women of reproductive age, the condition leads to cyst filled ovaries and...
HAVE YOUR SAY
Log in to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.